Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The course of diffuse hyperthyroidism in Basedow disease].

E Schifferdecker1

  • 1Zentrum der Inneren Medizin, Universität Frankfurt/Main.

Fortschritte Der Medizin
|January 15, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2000
Same author

Circulating tumor necrosis factor alpha is elevated in male but not in female patients with type II diabetes mellitus.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·1997
Same author

Long-term adherence to intensified conventional insulin therapy.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·1995
Same author

[Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].

Medizinische Klinik (Munich, Germany : 1983)·1994
Same author

Long-term compliance of intensified insulin therapy.

Diabetes research and clinical practice·1994
Same author

HLA-DR3 and HLA-DR5 confer risk for autoantibody positivity against the thyroperoxidase (mic-TPO) antigen in healthy blood donors.

The Clinical investigator·1993
Same journal

[More information--less pain. Procedure in pain following amputation of limbs. Brachial plexus injury and nerve root avulsion. Interview by Susanne Kammerer].

Fortschritte der Medizin·1999
Same journal

[Galenic alternatives to unstable tocopherol acetate. "Smeared" or cheated?--Vitamin E in facial ointments].

Fortschritte der Medizin·1999
Same journal

[Gene diagnosis in the hand of the physician].

Fortschritte der Medizin·1999
Same journal

[Is non-toxic cancer therapy through biotechnology a possibility?].

Fortschritte der Medizin·1999
Same journal

[Smoking withdrawal in practice and clinic].

Fortschritte der Medizin·1999
Same journal

[The future of pancreas diagnosis. An exclusive training service of the Gastro-Ligue for dermatologists].

Fortschritte der Medizin·1999
See all related articles

Graves' disease, an autoimmune thyroid disorder, is chronic and requires lifelong management. Current treatments like thionamides and surgery have high relapse rates and may not offer lasting hyperthyroidism control.

Area of Science:

  • Endocrinology
  • Immunology

Context:

  • Graves' disease is a prevalent autoimmune disorder affecting the thyroid gland.
  • The condition necessitates long-term patient management due to its chronic nature.

Purpose:

  • To investigate the long-term management challenges of Graves' disease.
  • To evaluate the efficacy and limitations of current therapeutic strategies for Graves' disease.

Summary:

  • Graves' disease management is a prolonged process, often spanning a lifetime.
  • Drug therapy with thionamides results in a 60-70% relapse rate, with no reliable criteria to cease treatment.
  • Surgical interventions may also prove insufficient for sustained hyperthyroidism control.

Impact:

  • Highlights the need for improved diagnostic criteria for treatment cessation in Graves' disease.

Related Experiment Videos

  • Underscores the challenges in achieving lasting remission for autoimmune thyroid disorders.
  • Suggests a potential gap in current therapeutic approaches for Graves' disease management.